Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Document Type : Research article

Authors

1 Student’ Research Committee, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Department of Bone Marrow Transplant, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

5 Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Allogeneic hematopoietic stem cell transplantation (AHSCT) is a major method of treatment
for different hematologic and congenital disease. Graft versus host disease (GvHD) is a lifethreatening
adverse effect of AHSCT. Cyclosporine is the most important and common agent
for GvHD prophylaxis. Because of variable and unpredictable pharmacokinetics of cyclosporine
that produces different responses in each patients group and clinical setting, there are still lots of
uncertainties about its optimal method of administration and monitoring of this drug. Frequent
blood samples in eight different times were taken for cyclosporine quantification in twenty
AHSCT recipients and pharmacokinetic parameters determined in both intravenous (IV) and oral
administration and monitoring parameters assessed accordingly. Of pharmacokinetic parameters
mean ± SD area under concentration – time curve (AUC), clearance, and half-life were estimated
to be 5492 ± 1596 ng.h/mL, 19.44 ± 6.61 L/h, and 11.8 ± 5.4 h for IV and 7637.7 ± 2739.8 ng.h/
mL, 19.42 ± 6.62 L/h, and 11.16 ± 5.9 h for oral administration, respectively. Appropriate oral to
intravenous dosing ratio found to be about 1.6. Of monitoring parameters, C0.5 h and C6 showed
the highest coefficient of determination for regression between single points and total area under
curve. Evaluation of pharmacokinetic parameters derived from concentration versus time curve
showed that the appropriate oral/IV is 1.6 for maintenance GvHD prophylaxis for outpatients
could be helpful. Cyclosporine plasma concentration at 0.5 and 6 h after IV administration
showed the highest correlation with AUC of this drug.

Keywords

Main Subjects


(1) Schiff J, Cole E and Cantarovich M. Therapeutic
monitoring of calcineurin inhibitors for the
nephrologist. Clin. J. Am. Soc. Nephrol. (2007) 2:
374-84.
(2) Citterio F. Evolution of the therapeutic drug
monitoring of cyclosporine. Transplant. Proc.
(2004) 36 (2 Sppl): 420S-5S.
(3) Lukas JC, Suárez AM, Valverde MP, Calvo MV,
Lanao JM, Calvo R, Suarez E and Gil AD. Timedependent pharmacokinetics of cyclosporine
(Neoral) in de novo renal transplant patients. J.
Clin. Pharm. Ther. (2005) 30: 549-57.
(4) ELjebari H, Ben Fradj N, Salouage I, Gaies E,
Trabelsi S, Jebabli N, Lakhal M, Othman TB and 
313
Tafazoli A et al. / IJPR (2019), 18 (Special Issue): 302-314
Kouz A. Estimation of abbreviated cyclosporine A
area under the concentration-time curve in allogenic
stem cell transplantation after oral administration.
J. Transplant. (2012) 2012: 1-7.
(5) Schultz K, Nevill T, Balshaw R, Toze CL, Corr
T, Currie CJ, Strong DK and Keown PA. Effect
of gastrointestinal inflammation and age on
the pharmacokinetics of oral microemulsion
cyclosporin A in the first month after bone marrow
transplantation. Bone Marrow Transplant. (2000)
26: 545-51.
(6) Inoue Y, Saito T, Ogawa K, Nishio Y, Kosugi S,
Suzuki Y, Kato M, Sakai H, Takahashi M and Miura
I. Pharmacokinetics of cyclosporine a conversion
from twice-daily infusion to oral administration in
allogeneic hematopoietic stem cell transplantation.
Am. J. Ther. (2012) 21: 377-84.
(7) Zeighami S, Hadjibabaie M, Ashouri A, Sarayani
A, Khoee SH, Mousavi S, Radfar M and
Ghavamzadeh A. Assessment of cyclosporine
serum concentrations on the incidence of acute
graft versus host disease post hematopoietic stem
cell transplantation. Iran. J. Pharm. Res. (2014) 13:
305-312.
(8) Ruutu T, Gratwohl A, de Witte T, Afanasyev B,
Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte
R, Finke J, Garderet L, Greinix H, Holler E, Kröger
N, Lawitschka A, Mohty M, Nagler A, Passweg J,
Ringdén O, Socié G, Sierra J, Sureda A, WiktorJedrzejczak W, Madrigal A and Niederwieser D.
Prophylaxis and treatment of GVHD: EBMT-ELN
working group recommendations for a standardized
practice. Bone Marrow Transplant. (2014) 49: 168-
73.
(9) Parquet N, Reigneau O, Humbert H, Guignard M,
Ribaud P, Socié G, Devergie A, Espérou H and
Gluckman E. New oral formulation of cyclosporin
A (Neoral) pharmacokinetics in allogeneic bone
marrow transplant recipients. Bone Marrow
Transplant. (2000) 25: 965-8.
(10) Kimura S, Oshima K, Okuda S, Sato K, Sato M,
Terasako K, Nakasone H, Kako S, Yamazaki R,
Tanaka Y, Tanihara A, Higuchi T, Nishida J and
Kanda Y. Pharmacokinetics of CsA during the
switch from continuous intravenous infusion to
oral administration after allogeneic hematopoietic
stem cell transplantation. Bone Marrow
Transplant. (2010) 45: 1088-94.
(11) Dotti G, Gaspari F, Caruso R, Perico N, Remuzzi
G, Barbui T and Rambaldi A. Pharmacokinetic
study of the new cyclosporine-A formulation
(Neoral) in adult allogeneic bone marrow
transplant recipients. Haematologica (2001) 86:
311-5.
(12) Papachristou F, Gakis D, Sotiriou I, Liatsis I,
Takoudas D and Antoniadis A. Pharmacokinetic
study of twice vs. thrice daily dosing of
Sandimmun Neoral in pediatric renal transplant
patients. Transplant. Proc. (1998) 30: 1988-90.
(13) Choi JS, Lee SH, Chung SJ, Yoo KH, Sung KW
and Koo HH. Assessment of converting from
intravenous to oral administration of cyclosporin
A in pediatric allogeneic hematopoietic stem cell
transplant recipients. Bone Marrow Transplant.
(2006) 38: 29-35.
(14) Koristkova B, Grundmann M, Brozmanova H,
Perinova I and Safarcik K. Validation of sparse
sampling strategies to estimate cyclosporine A
area under the concentration-time curve using
either a specific radioimmunoassay or highperformance liquid chromatography method.
Ther. Drug Monit. (2010) 32: 586-93.
(15) Quilitz R. Cyclosporine monitoring in allogeneic
bone marrow transplantation. J. Oncol. Pharm.
Pract. (1996) 2: 27-32.
(16) Donnelly J, Blijlevens N and Schattenberg A.
Monitoring cyclosporine using blood drawn via a
central venous catheter. Bone Marrow Transplant.
(2003) 32: 1037.
(17) David O and Johnston A. Limited sampling
strategies for estimating cyclosporine area under
the concentration-time curve: review of current
algorithms. Ther. Drug Monit. (2001) 23: 100-14.
(18) Schrauder A, Saleh S, Sykora K, Hoy H, Welte K,
Boos J, Hempel G and Grigull L. Pharmacokinetic
monitoring of intravenous cyclosporine A in
pediatric stem-cell transplant recipients. The
trough level is not enough. Pediatr. Transplant.
(2009) 13: 444-50.
(19) Hadjibabaie M, Vazirian I, Iravani M, Moosavi
SA, Alimoghaddam K, Ghavamzadeh A and
Rezaee S. Development and validation of limited
sampling strategies forestimation of cyclosporine
area under the concentration-time curve in
hematopoietic stem cell transplant patients. Ther.
Drug Monit. (2011) 33: 673-80.
(20) Barkholt L, Remberger M, Bodegård H, Ringdén
O and Böttiger Y. Cyclosporine A(CsA) 2-h
concentrations vary between patients without
correlation to graft-versus-host disease
after allogeneic haematopoietic stem cell
transplantation. Bone Marrow Transplant. (2007)
40: 683-9.
(21) Morris RG. Cyclosporin therapeutic drug
monitoring - an established service revisited.
Clin. Biochem. Rev. (2003) 24: 33–46.
(22) Hilbrands LB, Hoitsma AJ, van den Berg J and
Koene RAP. Cyclosporin A blood levels during 
314
Cyclosporine pharmacokinetic and dosing for GVHD prophylaxis
use of cyclosporin as oral solution or in capsules:
comparison of pharmacokinetic parameters.
Transpl. Int. (1991) 4: 125-7.
(23) Willemze AJ, Press RR, Lankester AC, Egeler
RM, den Hartigh J and Vossen JM. CsA exposure
is associated with acute GVHD and relapse in
children after SCT. Bone Marrow Transplant.
(2010) 45: 1056-61.
(24) Dupuis L, Seto W, Teuffel O, Gibson P, Schultz
KR, Doyle JD, Gassas A, Egeler RM, Sung L
and Schechter T. Prediction of area under the
cyclosporine concentration versus time curve
in children undergoing hematopoietic stem cell
transplantation. Biol. Blood Marrow Transplant.
(2013) 19: 418-23.
(25) Hendriks M, Blijlevens N, Schattenberg A, Burger
DM and Donnelly JP. Cyclosporine short infusion
and C2 monitoring in haematopoietic stem cell
transplant recipients. Bone Marrow Transplant.
(2006) 38: 521-5.
(26) Mahalati K, Belitsky P, West K, Kiberd B, Fraser
A, Sketris I, Macdonald AS, McAlister V and
Lawen J. Approaching the therapeutic window
for cyclosporine in kidney transplantation: a
prospective study. J. Am. Soc. Nephrol. (2001) 12:
828-33.
(27) Wilhelm AJ, de Graaf P, Veldkamp AI, Janssen
JJWM, Huijgens P and Swart EL. Population
pharmacokinetics of ciclosporin in haematopoietic
allogeneic stem cell transplantation with emphasis
on limited sampling strategy. Br. J. Clin.
Pharmacol. (2012) 73: 553-63.
(28) Johnston A, Sketris I, Marsden JT, Galustian CG,
Fashola T, Taube D, Pepper J and Holt DW. A
limited sampling strategy for the measurement of
cyclosporine AUC. Transplant. Proc. (1990) 22:
1345-6.
(29) Gaspari F, Anedda M, Signorini O, Remuzzi G and
Perico N. Prediction of cyclosporine area under the
curve using a three-point sampling strategy after
Neoral administration. J. Am. Soc. Nephrol. (1997)
8: 647-52.
(30) Mahalati K, Belitsky P, Sketris I, West K and
Panek R. Neoral monitoring by simplified sparse
sampling area under the concentration-time curve:
its relationship to acute rejection and cyclosporine
nephrotoxicity early after kidney transplantation.
Transplantation (1999) 68: 55-62.
(31) Morris R, Russ G, Cervelli M, Juneja R, McDonald
S and Mathew T. Comparison of trough, 2-hour,
and limited AUC blood sampling for monitoring
cyclosporin (Neoral) at day 7 post-renal
transplantation and incidence of rejection in the
first month. Ther. Drug Monit. (2002) 24: 479-86.
(32) Kagawa Y, Sawada J, Yamada S, Matsuda
H, Kageyama S, Masuya M, Shiku H and
Kojima M. Relationship between development
of nephrotoxicity and blood concentration of
cyclosporine A in bone-marrow transplanted
recipients who received the continuous intravenous
infusion. Biol. Pharm. Bull. (2003) 26: 1115-9.
(33) Zager RA, O’Quigley J, Zager BK, Alpers CE,
Shulman HM, Gamelin LM, Stewart P and Thomas
ED. Acute renal failure following bone marrow
transplantation: a retrospective study of 272
patients. Am. J. Kidney Dis. (1989) 13: 210-6.
(34) Helal I, Byzun A, Rerolle JP, Morelon E,
Kreis H and Bruneel-Mamzer MF. Acute renal
failure following allogeneic hematopoietic cell
transplantation: incidence, outcome and risk
factors. Saudi J. Kidney Dis. Transpl. (2011) 22:
437-43.
(35) Noè A, Cappelli B, Biffi A, Chiesa R, Frugnoli I,
Biral E, Finizio V, Baldoli C, Vezzulli P, Minicucci
F, Fanelli G, Fiori R, Ciceri F, Roncarolo
MG and Marktel S. High incidence of severe
cyclosporine neurotoxicity in children affected
by haemoglobinopaties undergoing myeloablative
haematopoietic stem cell transplantation: early
diagnosis and prompt intervention ameliorates
neurological outcome. Ital. J. Pediatr. (2010) 36:
14.
(36) Loughran TJ Jr, Deeg HJ, Dahlberg S, Kennedy
MS, Storb R and Thomas ED. Incidence of
hypertension after marrow transplantation among
112 patients randomized to either cyclosporine
or methotrexate as graft-versus-host disease
prophylaxis. Br. J. Haematol. (1985) 59: 547-53.
(37) Tor O and Garg R. Atypical diabetes mellitus
associated with bone marrow transplantation.
Endocr. Pract. (2010) 16: 93-6.